Pulmonary epithelioid inflammatory myofibroblastic sarcoma with multiple bone metastases: case report and review of literature

Diagnostic Pathology

Zhi Li³  Xiao-ying Tian¹  Juhong Jiang²  Xinge Fu² 

[1] School of Chinese Medicine, Hong Kong Baptist University, 7, Baptist University Road, Kowloon Tong, Hong Kong, China;Department of Pathology, The First Affiliated Hospital, Guangzhou Medical University, 151, Yanjiang Road, Guangzhou 510120, China;Department of Pathology, The First Affiliated Hospital, Sun Yat-sen University, 58, Zhongshan Road II, Guangzhou 510080, China

关键词: Prognosis;    Differential diagnosis;    Anaplastic lymphoma kinase;    Inflammatory myofibroblastic tumor;    Epithelioid inflammatory myofibroblastic sarcoma;   

Others  :  1225966
DOI  :  10.1186/s13000-015-0358-1

 received in 2015-04-28, accepted in 2015-07-09,  发布年份 2015

【 摘 要 】

Epithelioid inflammatory myofibroblastic sarcoma (EIMS) is a rare variant of inflammatory myofibroblastic tumor with distinctive morphological features and malignant clinical behavior. Only a few such cases have been described in the literature. We report here a case of unusual pulmonary EIMS with multiple bone metastases. A 21-year-old Chinese male patient presented with complaints of general fatigue and rapid weight loss, and a huge tumor arising in the left lower lobe of lung was detected by chest computed tomography. The mass of lung was totally resected. Microscopically, the tumor cells were rounded and epithelioid in shape. Myxoid stroma and inflammatory infiltration was also present. The tumor cells were immunopositive to anaplastic lymphoma kinase (ALK) in smooth cytoplasmic pattern. Fluorescence in situ hybridization (FISH) assay revealed the presence of rearrangement of ALK gene. Three months after lung surgery, there were multiple bone metastases and intraspinal mass found by positron emission tomography. The second surgical treatment was performed to remove the intraspinal lesion. The histological and immunohistochemical features of intraspinal mass were similar to those of pulmonary tumor. The diagnosis of pulmonary EIMS with multiple bone metastases was made. To the best of our knowledge, it may be the first case of an EIMS arising in lung. Awareness of EIMS in respiratory tract and its distinctive features is important for pathologists to avoid a diagnostic pitfall caused by histologic similarities to other ALK-positive tumors. ALK inhibitor is a promising treatment for this aggressive tumor regardless of its potential acquired resistance.

【 授权许可】

   
2015 Fu et al.

【 图 表 】

Fig. 1.

Fig. 2.

Fig. 3.

【 参考文献 】

• [1]Coffin CM, Fletcher JA. Inflammatory myofibroblastic tumor. In: World Health Organization classification of tumors of soft tissue and bone. Fletcher CDM, Bridge JA, Hogendoorn PCW, Mertens F, editors. IARC Press, Lyon; 2013: p.83-4.
• [2]Mariño-Enríquez A, Wang WL, Roy A, Lopez-Terrada D, Lazar AJ, Fletcher CD et al.. Epithelioid inflammatory myofibroblastic sarcoma: An aggressive intra-abdominal variant of inflammatory myofibroblastic tumor with nuclear membrane or perinuclear ALK. Am J Surg Pathol. 2011; 35:135-44.
• [3]Kozu Y, Isaka M, Ohde Y, Takeuchi K, Nakajima T. Epithelioid inflammatory myofibroblastic sarcoma arising in the pleural cavity. Gen Thorac Cardiovasc Surg. 2014; 62:191-4.
• [4]Kimbara S, Takeda K, Fukushima H, Inoue T, Okada H, Shibata Y et al.. A case report of epithelioid inflammatory myofibroblastic sarcoma with RANBP2-ALK fusion gene treated with the ALK inhibitor, crizotinib. Jpn J Clin Oncol. 2014; 44:868-71.
• [5]Suzuki R, Seto M, Nakamura S, Nakagawa A, Hara K, Takeuchi K. Sarcomatoid variant of anaplastic large cell lymphoma with cytoplasmic ALK and alpha-smooth muscle actin expression: a mimic of inflammatory myofibroblastic tumor. Am J Pathol. 2001; 159:383-4.
• [6]Cook JR, Dehner LP, Collins MH, Ma Z, Morris SW, Coffin CM et al.. Anaplastic lymphoma kinase (ALK) expression in the inflammatory myofibroblastic tumor: a comparative immunohistochemical study. Am J Surg Pathol. 2001; 25:1364-71.
• [7]Cessna MH, Zhou H, Sanger WG, Perkins SL, Tripp S, Pickering D et al.. Expression of ALK1 and p80 in inflammatory myofibroblastic tumor and its mesenchymal mimics: a study of 135 cases. Mod Pathol. 2002; 15:931-8.
• [8]Morris SW, Kirstein MN, Valentine MB, Dittmer KG, Shapiro DN, Saltman DL et al.. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin’s lymphoma. Science. 1994; 263:1281-4.
• [9]Lawrence B, Perez-Atayde A, Hibbard MK, Rubin BP, Dal Cin P, Pinkus JL et al.. TPM3-ALK and TPM4-ALK oncogenes in inflammatory myofibroblastic tumors. Am J Pathol. 2000; 157:377-84.
• [10]Bridge JA, Kanamori M, Ma Z, Pickering D, Hill DA, Lydiatt W et al.. Fusion of the ALK gene to the clathrin heavy chain gene, CLTC, in inflammatory myofibroblastic tumor. Am J Pathol. 2001; 159:411-5.
• [11]Cools J, Wlodarska I, Somers R, Mentens N, Pedeutour F, Maes B et al.. Identification of novel fusion partners of ALK, the anaplastic lymphoma kinase, in anaplastic large-cell lymphoma and inflammatory myofibroblastic tumor. Genes Chromosomes Cancer. 2002; 34:354-62.
• [12]Debiec-Rychter M, Marynen P, Hagemeijer A, Pauwels P. ALK-ATIC fusion in urinary bladder inflammatory myofibroblastic tumor. Genes Chromosomes Cancer. 2003; 38:187-90.
• [13]Gleason BC, Hornick JL. Inflammatory myofibroblastic tumours: where are we now? J Clin Pathol. 2008; 61:428-37.
• [14]Chen ST, Lee JC. An inflammatory myofibroblastic tumor in liver with ALK and RANBP2 gene rearrangement: combination of distinct morphologic, immunohistochemical, and genetic features. Hum Pathol. 2008; 39:1854-8.
• [15]Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S et al.. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 2007; 448:561-6.
• [16]Debelenko LV, Raimondi SC, Daw N, Shivakumar BR, Huang D, Nelson M et al.. Renal cell carcinoma with novel VCL-ALK fusion: new representative of ALK-associated tumor spectrum. Mod Pathol. 2011; 24:430-42.
• [17]Mano H. ALKoma: a cancer subtype with a shared target. Cancer Discov. 2012; 2:495-502.
• [18]Fabre D, Fadel E, Singhal S, de Montpreville V, Mussot S, Mercier O et al.. Complete resection of pulmonary inflammatory pseudotumors has excellent long-term prognosis. J Thorac Cardiovasc Surg. 2009; 137:435-40.
• [19]Sakurai H, Hasegawa T, Watanabe SI, Suzuki K, Asamura H, Tsuchiya R. Inflammatory myofibroblastic tumor of the lung. Eur J Cardiothorac Surg. 2004; 25:155-9.
• [20]Butrynski JE, D’Adamo DR, Hornick JL, Dal Cin P, Antonescu CR, Jhanwar SC et al.. Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor. N Engl J Med. 2010; 363:1727-33.
• [21]Fujiya M, Kohgo Y. ALK inhibition for the treatment of refractory epithelioid inflammatory myofibroblastic sarcoma. Intern Med. 2014; 53:2177-8.
• [22]Kurihara-Hosokawa K, Kawasaki I, Tamai A, Yoshida Y, Yakushiji Y, Ueno H et al.. Epithelioid inflammatory myofibroblastic sarcoma responsive to surgery and an ALK inhibitor in a patient with panhypopituitarism. Intern Med. 2014; 53:2211-4.
• [23]Gainor JF, Shaw AT. Emerging paradigms in the development of resistance to tyrosine kinase inhibitors in lung cancer. J Clin Oncol. 2013; 31:3987-96.
• [24]Sasaki T, Okuda K, Zheng W, Butrynski J, Capelletti M, Wang L et al.. The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers. Cancer Res. 2010; 70:10038-43.
• [25]Chen Z, Akbay E, Mikse O, Tupper T, Cheng K, Wang Y et al.. Co-clinical trials demonstrate superiority of crizotinib to chemotherapy in ALK-rearranged non-small cell lung cancer and predict strategies to overcome resistance. Clin Cancer Res. 2014; 20:1204-11.